Authors

Latest:

Moving to Electronic Prior Authorization Requires Incremental Steps

In a time of tremendous technological advancement, how is it that 90% of communications between providers and payers for prior authorizations are still done by phone or fax, and how do we move to more automated processes?1

Nathan A. Pennell, MD, PhD

Latest:

Dr. Pennell on Understanding the Cost-Effectiveness of Osimertinib in NSCLC

Nathan A. Pennell, MD, PhD, discusses the importance of understanding the cost-effectiveness of osimertinib in non–small cell lung cancer.

Nathan Fowler, MD

Latest:

Dr. Fowler on Different Responses to Therapy for Follicular Lymphoma

Nathan Fowler, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the differences in response to the same therapy for patients with follicular lymphoma.

Nathan Fowler, MD, The University of Texas MD Anderson Cancer Center

Nathan Fowler, MD, University of Texas MD Anderson Cancer Center

Nathan H. Fowler, MD, MD Anderson Cancer Center

Latest:

Hematologic Malignancies Talk: Exciting Updates from ASH 2020 Virtual Meeting

Nathan H. Fowler, MD, University of Texas MD Anderson Cancer Center

Nathan Hale, DO, MS

Latest:

Balancing Family With Career Goals During an Oncology Fellowship

Successfully attaining our goals in fellowship is demanding. They are accomplished by establishing work/life balance.

Nathan Pennell, MD, PhD

Latest:

Dr. Pennell on the Risks Associated With Sequential Therapy With Immunotherapy/TKIs in Lung Cancer

Nathan A. Pennell, MD, PhD, discusses the risks that are associated with sequential therapy with immunotherapy and TKIs in lung cancer.

Naval Daver, MD

Latest:

Dr Daver on the Evolution of Survivorship and Treatment Outcomes in AML

Naval G. Daver, MD, discusses the evolution of survivorship in patients with acute myeloid leukemia.

Naval Daver, MD, The University of Texas MD Anderson Cancer Center

Naval Daver, MD, University of Texas MD Anderson Cancer Center

Naval G. Daver, MD

Latest:

Dr Daver on the Potential Role for Menin Inhibitors in Frontline AML

Naval G. Daver, MD, discusses the potential role for menin inhibitors in the frontline treatment of patients with acute myeloid leukemia.

Naval G. Daver, MD, MD Anderson Cancer Center

Latest:

Dr Daver on the Potential Role of MRD Assessment in AML Treatment

Naval G. Daver, MD, discusses the potential role of minimal residual disease assessments in acute myeloid leukemia.

Naval G. Daver, MD The University of Texas MD Anderson Cancer Center

Naveed Saleh, MD, MS

Latest:

Navigating Treatment Options for Patients With Early-Stage Breast Cancer

Genetic advances have helped elucidate the heterogenous nature of breast cancer, however optimal strategies for patients with early-stage disease still need to be ironed out.

Naveed Zafar Janjua, MBBS, MSc, DrPH

Latest:

Dr. Naveed Zafar Janjua on Impact of Hepatitis C Treatment Timing on HCC Risk

Naveed Zafar Janjua, MBBS, MSc, DrPH, senior scientist, clinical prevention services, BC Centre for Disease Control and clinical associate professor, School of Population and Public Health, University of British Columbia, discusses the findings from the British Columbia hepatitis testers cohort, which looked at the impact of hepatitis infection on long term risk of hepatocellular carcinoma (HCC).

Naveen Pemmaraju, MD

Latest:

Exploring the Future of MF Treatment

The panel closes their discussion by highlighting novel agents in the treatment of myeloproliferative neoplasms to look out for.

Navesh K. Sharma, DO, PhD

Latest:

Dr. Sharma on Tolerability of SIRT in Patients With CRC

Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the safety profile of selective internal radiation therapy (SIRT) when added to chemotherapy for patients with colorectal cancer (CRC) that has metastasized to the liver.

Neal D. Shore, MD

Latest:

ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)

Panelists discuss how the CONTACT-02 trial highlights the potential of cabozantinib combined with atezolizumab in improving treatment outcomes for patients with advanced cancer.